Brodowska-Kania Dorota, Kotwica Ewa, Paturej Aleksandra, Sośnicki Witold, Patera Janusz, Giżewska Agnieszka, Niemczyk Stanisław
Department of Internal Medicine, Nephrology and Dialysis, Military Institute of Medicine, Warsaw, Poland.
Department of General Surgery, Oncology, Metabolic and Thoracic Surgery, Military Institute of Medicine, Warsaw, Poland.
Nagoya J Med Sci. 2016 Dec;78(4):507-516. doi: 10.18999/nagjms.78.4.507.
Pulmonary blastoma (PB) is a rare form of lung tumour and is accountable for 0.25-0.5% of primary pulmonary malignancies. Initially pulmonary blastoma was divided into three subtypes: biphasic pulmonary blastoma (BPB) consisting of an epithelial and mesenchymal component, well differentiated fetal adenocarcinoma (WDFA) built of well differentiated epithelium and a mesenchymal component and malignant pleuropulmonary blastoma (PPB). Prognosis in this type of cancer is really poor. We present a current review of literature and a clinical case report. Treatment of PB is very difficult. Data and recommendations about the treatment of pulmonary blastoma are still available therefore we should use only observations and clinical case reports.
肺母细胞瘤(PB)是一种罕见的肺肿瘤形式,占原发性肺恶性肿瘤的0.25 - 0.5%。最初,肺母细胞瘤分为三种亚型:由上皮和间充质成分组成的双相性肺母细胞瘤(BPB)、由高分化上皮和间充质成分构成的高分化胎儿腺癌(WDFA)以及恶性胸膜肺母细胞瘤(PPB)。这类癌症的预后非常差。我们呈现了一篇当前的文献综述及一份临床病例报告。肺母细胞瘤的治疗非常困难。关于肺母细胞瘤治疗的数据和建议仍然有限,因此我们只能参考观察结果和临床病例报告。